Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
IPO Year:
Exchange: NASDAQ
Website: plustherapeutics.com
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx, a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a Manufacturing Services Agreement (MSA) for the production of Rhenium (186Re) Obisbemeda, an innovative radiotherapy for CNS cancers, including leptomeningeal metastases and recurrent glioblastoma. "In 2025, we intend to begin late-stage clinical trials and are actively preparing for commercial level product demand, therefore now is the time to expand our suppl
AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, November 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/rdthwekoDial-in Link:http
Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development Company will present results from the FORESEE Trial of circulating tumors cells for improved diagnosis and disease monitoring of LM Company to host an educational symposium featuring clinical experts discussing LM and Plus' recent announcements for its LM therapeutic and diagnostic programs AUSTIN, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with
Rhenium (186Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical centers in New York and Upper Midwest AUSTIN, Texas, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers presented an update on the ongoing ReSPECT-GBM Phase 1/2
AUSTIN, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, will present data at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting September 28 - October 2, in Houston, Texas. Presentation: TitleTreatment of Recurrent Glioblastoma (rGBM) via Convection Enhanced Delivery (CED) with Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome, 186RNL): ReSPECT-GBM Phase 2 Trial Update PresenterJohn Floyd, M.D., Associate Professor and Chairman Neurosurgery, UT Health Science San An
AUSTIN, Texas, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel. Presentation Time: Monday, September 9, 2024, available on-demand starting at 7:00 AM ET Webcast Link: Here A replay of this presenta
Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trialManagement to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the second quarter ended June 30, 2024, and provided an overview of recent and upcoming business highlights. Q2 2024 RECENT HIG
Plus' CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytology and influenced clinical management decisions in over 90% of LM cases AUSTIN, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data from the FORESEE study of its CNSide platform for the diagnosis and management of LM. The data were presented in a podium presentation a
Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data in a podium presentation updating the progress of its ReSPECT-LM clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) in lepto
AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference CallDate/Time:Wednesday, August 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/mtnrwhh5Dial-in Link:https:/
424B3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
S-3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
424B3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
S-8 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
424B3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
424B3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
10-Q - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced the appointment of Pius Maliakal, M. Pharm., Ph.D., as Vice President of Clinical Operations. Dr. Maliakal will be responsible for the strategy and planning of key clinical operational initiatives, focusing on advancing the Company's lead clinical trials, ReSPECT-GBM and ReSPECT-LM, and further developing the broader pipeline. Dr. Maliakal is an accomplished R&D professional who brings over 20 years of global and domestic
AUSTIN, Texas, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the appointment of Norman LaFrance, M.D. to the position of Chief Medical Officer and Senior Vice President. "We are delighted to have Dr. LaFrance onboard as he brings several decades of highly relevant clinical, regulatory and commercial expertise to the Plus Therapeutics management team," stated Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. "His proven track record in radiotherapeutics and drug developme
HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy
HC Wainwright & Co. initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $7.00
Ladenburg Thalmann initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $8.00
LADENBURG THALM/SH SH initiated coverage of Plus Therapeutics with a rating of Buy
The Company received notice of an advance payment of $3.3 million from CPRIT, part of the $17.6 million award granted in September 2022.
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1.09) by 31.19 percent. This is a 63.77 percent increase over losses of $(2.07) per share from the same period last year. The company reported quarterly sales of $1.677 million which missed the analyst consensus estimate of $1.688 million by 0.62 percent. This is a 231.42 percent increase over sales of $506.000 thousand the same period last year.
Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, "CNSide™" and discussed potential partnering opportunities CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rhenium (Re186) obisbemedaCompany summarized topline data from the FORESEE clinical trial planned for complete presentation at the SNO/ASCO Meeting in August 2024Call replay & transcript available via the link below
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs. The award is expected to commence in Q3 2024 and will support the planned expansion of the company's clinical trial for pediatric brain cancer. "This recent award further extends our current cash runway in the second half of 2025 while supporting the 2024 expansion of our clinical development activities," said Marc Hedrick, President & CEO of Plus Therapeutics. "In 2023, the company applied for approximately $7 million in grant funding, and we plan to file for more than $10 million in fu
Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trialsControlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation
AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, November 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/rdthwekoDial-in Link:http
Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trialManagement to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the second quarter ended June 30, 2024, and provided an overview of recent and upcoming business highlights. Q2 2024 RECENT HIG
AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference CallDate/Time:Wednesday, August 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/mtnrwhh5Dial-in Link:https:/
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus' clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous
AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 15, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference CallWednesday, May 15, 2024 @ 5:00 PM ETDial-in Link: https://register.vevent.com/register/BI7282c3e944b0498483eb5b57757ccaad
Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio Company will summarize topline data from the FORESEE clinical trial planned for presentation at the SNO/ASCO Meeting in August 2024 Management call scheduled for Thursday, May 9th, 2024 at 8:30 AM ET AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces it will host an investor call on Thursday, May 9th, 2024 at 8:30 AM ET to discuss the strategic acquisition of the
Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement to expand ReSPECT-GBM Phase 2 trial and add new sites Current financial forecast for sufficient runway to fund operations into 2H 2025 Management to Host Conference Call March 5, 2024 at 5:00 p.m. ET AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial result
AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Conference Call & Webcast Tuesday, March 5, 2024 @ 5:00 PM ET Dial-in Link:https://register.vevent.com/register/BIa3e26b40a05b4e7185cb3d97
New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium (186Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17th; Company will also host a Key Opinion Leader (KOL) event following the meeting to discuss the results Completed dosing in Cohort 4 of the Phase 1 ReSPECT-LM dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases, the first of four additional planned cohorts in Part B (Cohorts 4-7); an update will also be provided at the SNO meeting in November Current cash of $11 million, plus an additional $10.2 million expected through the end of 2024 from the Cancer Prevention & Res
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2023 financial results on Tuesday, October 31, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Conference Call & WebcastTuesday, October 31, 2023 @ 5:00 PM ETDial in #:https://register.vevent.com/register/BI484eba10ce0d4bc292c51db6fc396f0cWebcas